Najib Ben Khaled, Marie Möller, Leonie S Jochheim, Catherine Leyh, Ursula Ehmer, Katrin Böttcher, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Alexander Weich, Hans Benno Leicht, Valentina Zarka, Liangtao Ye, Julia Schneider, Ignazio Piseddu, Osman Öcal, Monika Rau, Friedrich Sinner, Marino Venerito, Simon Johannes Gairing, Friedrich Förster, Julia Mayerle, Enrico N De Toni, Andreas Geier, Florian P Reiter
BACKGROUND & AIMS: Atezolizumab/bevacizumab (atezo/bev) and lenvatinib have demonstrated efficacy as first-line therapies for hepatocellular carcinoma (HCC). However, vascular endothelial growth factor (VEGF) inhibition with these therapies may be associated with the risk of bleeding and thromboembolic events. In this study, we evaluated the efficacy and safety with focus on the bleeding and thromboembolic events of atezo/bev vs . lenvatinib in a large, multicenter real-world population...
June 2024: JHEP reports: innovation in hepatology